Drug-Induced Gynecomastia
| Autor: | John D. Bowman, Hyunah Kim, Juan J. Bustamante |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Drug Drug-Related Side Effects and Adverse Reactions Antiandrogens medicine.drug_class media_common.quotation_subject Pharmacology Bioinformatics chemistry.chemical_compound Adverse Event Reporting System Adverse Drug Reaction Reporting Systems Humans Medicine Protease Inhibitors Pharmacology (medical) Cimetidine skin and connective tissue diseases Adverse effect media_common business.industry Androgen Antagonists Estrogens medicine.disease chemistry Gynecomastia Estrogen Androgens Spironolactone Reverse Transcriptase Inhibitors business medicine.drug |
| Zdroj: | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 32:1123-1140 |
| ISSN: | 0277-0008 |
| Popis: | Drugs account for about 20% of gynecomastia cases in men. As a number of factors can alter the estrogen:androgen ratio, several pathophysiologic mechanisms are associated with drugs causing this disorder. Antiandrogens, protease inhibitors, and nucleoside reverse transcriptase inhibitors are the most common drug causes of gynecomastia, whereas first-generation antipsychotics, spironolactone, verapamil, and cimetidine are less common causes. Other drugs have been reported rarely as causes. Treatment may involve switching to an alternative agent or may require surgery or irradiation if the causative agent cannot be discontinued. We reviewed the literature on drug-induced gynecomastia and provided another perspective by reviewing data from the United States Food and Drug Administration's Adverse Event Reporting System. Epidemiologic studies are needed to provide a more accurate description of the frequency of drug-induced gynecomastia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text